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Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory
disease, which involves the spine, peripheral joints
and entheses. By definition, juvenile-onset ankylosing
spondylitis (JAS) is when the onset of AS occurs at
less than 16 years of age.1 In previous studies, the
prevalence of JAS in AS patients varied from 9% to 21%
in Caucasian populations, but was ≥ 40% in Mexican
Mestizo and Korean AS patients.2 In daily practice, we
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have noted that patients with JAS and adult-onset anky-
losing spondylitis (AAS) have different clinical mani-
festations. Some studies found that delayed diagnosis,
joint deformity, and functional impairment were more
frequent in patients with JAS than AAS.3,4 Another
study observed a comparable functional outcome bet-
ween JAS and AAS patients.5 A recent study reported
that AAS was associated with worse functional and
quality of life measures, and higher fatigue scores, after
adjustment for disease duration.6
Do JAS and AAS patients have different disease
courses because of different etiologies? HLA-B27 
was noted to be closely related to AS in 1973. Some
other genes, such as HLA-B60, B61, CYP2D6, and
interleukin-1β, were later found to relate to AS.7 In
previous studies, gastrointestinal (GI)/genitourinary
(GU) infection was shown to be associated with spondy-
loarthropathies (SpAs). The pathogens Klebsiella pneu-
moniae, Salmonella enteritidis, and Escherichia coli were
found to relate to AS.8–13 Physical trauma was also be-
lieved to trigger the development of SpAs in several re-
ports.14–17 New antigens released from trauma,18 deep
Koebner’s phenomenon,19 and neuropeptite substance
P released from peripheral nerve terminals20 were sug-
gested to initiate the autoimmune reactions of SpAs in
physical trauma. However, some authors have not iden-
tified this phenomenon.21,22 In this study, we compared
the possible risk factors of AS, such as HLA-B27, GI/
GU infection, physical trauma, intense physical train-
ing and heavy working in JAS and AAS.
Until now, there have been no integral compar-
isons of clinical manifestations, disease activity, radio-
logical and functional outcomes between JAS and AAS
groups in Chinese populations. The present study was
undertaken to compare the disease courses of these 
2 patient groups in Taiwan.
Methods
Subjects
We enrolled AS patients who visited the rheumato-
logic clinic of a tertiary medical center during the period
from January 1 to June 30 in 2006. All of the patients
fulfilled the 1984 modified New York criteria for AS.
Patients were included if they had received regular
follow-up at the clinic for more than 3 months, and
taken prescribed medication (including nonsteroidal
anti-inflammatory drugs [NSAIDs], corticosteroids,
disease-modifying antirheumatic drugs [DMARDs],
antitumor necrosis factors [anti-TNF], or other symp-
tomatic treatment) with good compliance (≥ 90%) in
the 3 months prior to the interviewing day. A total of
169 patients (142 males, 27 females) entered into our
series. Each participant provided informed consent, and
the performance of this study was approved by the
research ethics committee of the hospital.
Questionnaire
During face-to-face interviews, each patient completed
a comprehensive questionnaire that was composed of
5 main sections: (1) basic personal data; (2) factors
possibly related to AS (GI or GU infection, physical
trauma history which made a patient visit a doctor,
intense physical training, heavy work) in the 1 month
antecedent to disease onset, and history of military
service; (3) family history (relatives within the third
degree) of AS and other SpAs, uveitis, psoriasis, inflam-
matory bowel disease (IBD); (4) disease course (age
at disease onset, symptoms, diagnosis and treatment)
and extramusculoskeletal manifestations (uveitis, im-
munoglobulin A [IgA] nephropathy, and colitis diag-
nosed by specialists); (5) Bath AS indices with a
0–10 cm visual analog scale (VAS),23 including the
Bath AS Disease Activity Index (BASDAI),24 Bath AS
Functional Index (BASFI),25 and Bath AS Patient
Global Assessment (BAS-G).26
Clinical evaluation
The medical chart of each patient was reviewed. A
single rheumatologist performed a thorough physical
examination for each subject, including any synovitis
or enthesitis, range of motion (ROM) of spine and
peripheral joints, and chest expansion. The value meas-
ured was then transformed into each item for the Bath
AS Metrology Index (BASMI).27 Physician’s Global
Assessment (PGA) score was evaluated with a 0–10 cm
VAS by the rheumatologist.
Laboratory tests
The erythrocyte sedimentation rate (ESR), serum 
C-reactive protein (CRP), and serum IgA are 3 markers
that are usually used to evaluate the disease activity of
AS. ESR was measured with the Westergren method.
Serum CRP and IgA levels were measured by neph-
elometry. The 3 indices were measured on the day of
the interview (present value). We also retrospectively
collected the values of the 3 indices recorded in the
medical chart on the 1st day of visit to our hospital for
AS (initial value) and the highest values during the
entire clinical course (peak value). In addition, HLA-
B27 typing was done by flow cytometry.
Radiography
Conventional plain films were used to assess disease
severity. Each film was evaluated by 1 radiologist and 
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1 rheumatologist (not the one performing physical exam-
ination). If there was a discrepancy, the 2 specialists
discussed and gave a conclusive grade or score. The
sacroiliac joint (SIJ) was graded as 1–4 with antero-
posterior pelvis view. Lateral views of the cervical and
lumbar spine were taken to score the modified Stoke
AS Spinal Score (mSASSS).28 Hip arthritis was evalu-
ated with anteroposterior and lateral views of the hip
joints.
Statistical analysis
The comparisons between JAS and AAS groups were
carried out using χ2 test or Fisher’s exact test for cate-
gorical variables, and Mann-Whitney U test or t test
for continuous variables as appropriate. A value of p
< 0.05 was considered statistically significant. Stati-
stical analyses were performed with SPSS version 14.0
(SPSS Inc., Chicago, IL, USA).
Results
There were 169 AS patients (47 JAS, 122 AAS) inclu-
ded in our study. The demographic data are shown in
Table 1. The gender distribution was similar for the 2
groups. The mean age of the JAS patients was signifi-
cantly younger than that of the AAS patients (26.9 ±
9.6 vs. 37.3 ± 11.7 years). A substantial proportion of
our patients (40.4% of JAS, 34.4% of AAS) had physical
trauma history in the 1 month before disease onset.
Additionally, 22.7% of JAS patients had intense physical
training, while 25.2% of AAS patients had heavy work
during the period. About half of the patients, in both
JAS and AAS groups, had family histories (relatives
within the third degree) of AS.
As Table 1 shows, the onset ages were 12.8 ± 2.7
and 25.0 ± 7.4 years for the JAS and AAS groups,
respectively. The disease duration was similar in the 2
groups (14.1 ± 9.7 years in JAS vs. 12.5 ± 9.5 years
in AAS), as were the years of delay in diagnosis (5.7 ±
6.3 years for JAS vs. 4.6 ± 6.8 years for AAS). The com-
parisons of clinical manifestations of JAS and AAS
patients are shown in Table 2. We divided the symp-
toms into 3 types: axial symptoms (including spine and
SIJ), peripheral enthesopathies, and peripheral arthri-
tis. The 2 groups had obvious differences in initial
symptoms, i.e. mainly peripheral enthesopathies and
arthritis in JAS patients, and mainly axial symptoms in
AAS patients (p < 0.001). In detail, the first involved
areas were pelvic entheses (23.9%), heel entheses
(23.9%), knee joints (19.6%), and hip joints (17.4%)
in the JAS group; while 57.8% of AAS patients ini-
tially presented with lumbar spine or SIJ pain. Also,
the 2 groups had diverse clinical courses during simi-
lar disease durations. All but 1 of the JAS patients had
some enthesopathies on any occasion. They had sig-
nificantly higher prevalence for pelvic and heel enthe-
sopathies, and hip and knee arthritis, than AAS patients.
As to extramusculoskeletal involvement, an interest-
ing finding was noted that a higher percentage of JAS
patients had uveitis, IgA nephropathy (IgAN), or coli-
tis, but the difference was significant only in IgAN.
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Table 1. Demographic characteristics of juvenile-onset and adult-onset ankylosing spondylitis patients*
Juvenile-onset AS (n = 47) Adult-onset AS (n = 122) p†
Male 41 (87.2) 101 (82.8) 0.480
Age (yr) 26.9 ± 9.6 (9–51) 37.3 ± 11.7 (19–69) < 0.001
Age at AS onset (yr) 12.8 ± 2.7 (5–16) 25.0 ± 7.4 (17–53) < 0.001
Duration of AS (yr) 14.1 ± 9.7 (1–39) 12.5 ± 9.5 (0–46) 0.330
Delay in diagnosis (yr) 5.7 ± 6.3 (0–28) 4.6 ± 6.8 (0–46) 0.358
Factors possibly related to AS‡
GI or GU infection 6 (12.8) 12 (9.8) 0.580
Physical trauma 19 (40.4) 42 (34.4) 0.467
Intense physical training§ 11 (22.7) 12 (10.1) 0.021
Heavy worker|| 2 (4.3) 34 (25.2) < 0.001
Family history of AS 24 (51.1) 62 (50.8) 0.977
Family history of other SpAs, 0 (0.0) 4 (3.3) 0.268
uveitis, IBD, psoriasis
*Data presented as n (%) for categorical variables and mean ± standard deviation (range) for continuous variables; †statistical significance if p < 0.05,
comparisons performed with c2 or Fisher’s exact test for categorical variables and t test for continuous variables; ‡histories of these factors in the 1 month
prior to AS onset; §intense physical training defined as a team player receiving strict and high amount of physical training; ||heavy worker defined as a worker
doing heavy labor, such as a house builder, painter, porter. AS = ankylosing spondylitis; GI = gastrointestinal; GU = genitourinary; SpAs = spondyloarthropathies;
IBD = inflammatory bowel disease.
The Bath AS indices and PGA score are listed in
Table 3. A trend was noted that BASDAI, BASMI
and PGA scores were higher in JAS patients, but only
significantly in the peripheral joint item of BASDAI
(p = 0.010) after adjustment for age and disease 
duration. The BASFI and BAS-G were comparable
for the 2 groups. Table 4 shows the laboratory data.
More than 97% of our patients had HLA-B27 in both
JAS and AAS. The CRP and ESR levels were higher in 
the JAS than the AAS group except for initial ESR. 
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Table 2. Comparison of clinical manifestations of juvenile-onset and adult-onset ankylosing spondylitis (AS) patients*
Juvenile-onset AS Adult-onset AS 
p†
(n = 47) (n = 122)
Initial symptoms < 0.001
Axial symptoms (including spinal 2 (4.3) 82 (66.9)
and sacroiliac joint)
Peripheral enthesopathy 28 (58.7) 23 (19.0)
Peripheral arthritis 17 (37.0) 17 (14.0)
Clinical symptoms at any time of disease
Low back pain 42 (89.4) 118 (96.7) 0.069
Middle back pain 22 (46.8) 73 (59.8) 0.126
Upper back pain 32 (68.1) 77 (63.1) 0.545
Any peripheral enthesopathy 46 (97.9) 88 (72.1) < 0.001
Pelvic enthesopathy‡ 34 (72.3) 54 (44.3) < 0.001
Knee enthesopathy§ 14 (29.8) 24 (19.7) 0.158
Heel enthesopathy|| 26 (55.3) 24 (19.7) < 0.001
Costosternal enthesopathy 16 (34.0) 50 (41.0) 0.407
Sausage digit 2 (4.3) 4 (3.3) 0.534
Any peripheral arthritis 37 (78.7) 55 (45.1) < 0.001
Hip joint 29 (61.7) 48 (39.3) 0.009
Knee joint 18 (38.3) 17 (13.9) 0.006
Foot (including ankle, tarsal, and toe arthritis) 11 (23.4) 14 (11.5) 0.050
Shoulder joint 6 (12.8) 13 (10.7) 0.697
Elbow joint 3 (6.4) 4 (3.3) 0.302
Hand joint (including wrist, carpal, 7 (14.9) 12 (9.8) 0.351
and finger arthritis)
Temporomandibular joint 1 (2.1) 4 (3.3) 0.573
Extramusculoskeletal involvement
Uveitis 17 (36.2) 27 (22.1) 0.062
IgA nephropathy 7 (14.0) 5 (3.7) 0.014
Colitis 4 (8.5) 7 (5.7) 0.501
*Data presented as n (%); †statistical significance if p < 0.05, comparisons performed with c2 or Fisher’s exact test; ‡pelvic enthesopathy, including enthesi-
tis over the iliac crest, anterior and posterior superior iliac spine, greater trochanter, ischial tuberosity, and pubis symphysis; §knee enthesopathy, including
patellar enthesitis and quadriceps enthesitis; ||heel enthesopathy, including Achilles enthesitis, plantar fasciitis, and tibialis posterior enthesitis.
Table 3. Bath ankylosing spondylitis indices and clinical evaluation of juvenile-onset versus adult-onset ankylosing spondylitis (AS) patients*
Juvenile-onset AS (n = 47) Adult-onset AS (n = 122) p† p‡
BASDAI (0–10) 3.84 ± 1.90 3.33 ± 1.89 0.108 0.598
BASFI (0–10) 1.81 ± 1.71 1.80 ± 1.86 0.941 0.529
BAS-G (0–10) 3.60 ± 2.25 3.54 ± 2.53 0.875 0.393
BASMI (0–10) 1.95 ± 2.16 1.64 ± 2.29 0.298 0.264
Chest expansion (cm) 5.35 ± 2.32 5.48 ± 2.06 0.682 0.118
PGA score (0–10) 2.40 ± 1.33 2.07 ± 1.09 0.152 0.610
*Measures were performed on the day of interview and data are presented as mean ± standard deviation; †statistical significance if p < 0.05, comparisons
performed with Mann-Whitney U test; ‡p value after adjustment for age and disease duration. BASDAI = Bath Ankylosing Spondylitis Disease Activity Index;
BASFI = Bath Ankylosing Spondylitis Functional Index; BAS-G = Bath Ankylosing Spondylitis Patient’s Global Assessment; BASMI = Bath Ankylosing Spondylitis
Metrology Index; PGA = Physician’s Global Assessment.
A slightly higher, but not significant, IgA in JAS
patients was noted.
The radiological evaluations are presented in
Table 5. SIJ grading was identical bilaterally in most
cases (86.1% of AAS and 85.1% of JAS), and differed
by only 1 grade in others. Therefore, we took the
severe side as the SIJ grade if the grading was unequal
bilaterally. There was no significant discrepancy in SIJ
grading and mSASSS in the 2 groups, although there
was a trend of higher mSASSS in AAS patients. 
On the other hand, the radiographic evidence of hip
joint involvement was much more common in the
JAS group, especially bilaterally, i.e. bilateral hip
involvement in 46.8% of JAS and 18.9% of AAS
patients, unilateral hip arthritis in 6.4% of JAS and
4.1% of AAS patients (p = 0.012 after adjustment for
age and disease duration).
Table 6 lists the therapies that these 169 patients
experienced. Most of our AS patients (97.9% of JAS and
95.1% of AAS) had received sulfasalazine treatment.
However, more JAS patients had taken methotrexate
and systemic (oral or intravenous) steroid than AAS
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Table 4. Laboratory data in juvenile-onset and adult-onset ankylosing spondylitis patients*
Juvenile-onset AS (n = 47) Adult-onset AS (n = 122) p†
Positive HLA-B27 46 (97.7) 119 (97.2) 0.691
ESR (mm/hr)
Initial 31.6 ± 23.5 27.9 ± 25.1 0.167
Peak 44.1 ± 28.9 34.6 ± 27.1 0.031
Present 27.3 ± 20.0 21.5 ± 21.0 0.027
CRP (mg/dL)
Initial 2.13 ± 2.41 1.13 ± 1.29 0.031
Peak 2.39 ± 2.49 1.37 ± 1.40 0.032
Present 1.82 ± 1.86 0.93 ± 1.06 0.007
IgA (mg/dL)
Initial 394.7 ± 163.2 360.7 ± 151.7 0.201
Peak 440.3 ± 172.4 393.6 ± 157.4 0.121
Present 382.2 ± 151.5 360.5 ± 140.5 0.356
*Data presented as n (%) for categorical variables and mean ± standard deviation for continuous variables; †statistical significance if p < 0.05, comparisons
performed with Fisher’s exact test for positive HLA-B27 and Mann-Whitney U test for others. AS = ankylosing spondylitis; ESR = erythrocyte sedimentation rate;
CRP = C-reactive protein; IgA = immunoglobulin A.
Table 5. Radiological evaluation of juvenile-onset and adult-onset ankylosing spondylitis patients*
Location
Juvenile-onset AS Adult-onset AS 
p† p‡
(n = 47) (n = 122)
Sacroiliac joint 0.266 0.463
Grade 0 0 (0) 0 (0)
Grade 1 0 (0) 0 (0)
Grade 2 17 (36.2) 52 (42.6)
Grade 3 8 (17.0) 26 (21.3)
Grade 4 22 (46.8) 44 (36.1)
Spine evaluated by mSASSS
Cervical spine (0–36) 2.74 ± 7.33 6.06 ± 12.13 0.306 0.325
Lumbar spine (0–36) 8.96 ± 9.98 11.59 ± 13.05 0.498 0.687
Sum of cervical and lumbar 9.58 ± 14.57 15.43 ± 23.43 0.704 0.345
spine (0–72)
Hip arthritis 0.001 0.012
Bilateral hip arthritis 22 (46.8) 23 (18.9)
Unilateral hip arthritis 3 (6.4) 5 (4.1)
No hip arthritis 22 (46.8) 94 (77.0)
*Data presented as n (%) for categorical variables and mean ± standard deviation for continuous variables; †statistical significance if p < 0.05, comparisons
performed with c2 test for categorical variables and Mann-Whitney U test for ordinal and continuous variables; ‡p value after adjustment for age and disease
duration. AS = ankylosing spondylitis; mSASSS = modified Stroke Ankylosing Spondylitis Spinal Score.
patients. There were only a few patients (2 JAS, 2
AAS) who had received anti-TNF therapy, due to lack
of reimbursement from the Taiwan National Health
Insurance. The symptomatic remedies in the 1 month
before the interviewing day, including NSAIDs, muscle
relaxants, acetaminophen, and anxiolytic agents, were
used similarly in the 2 groups. The 2 most common
operations in AS patients—total hip replacement and
spinal correction—were not significantly different
between the 2 groups.
Discussion
This is the first study that comprehensively compared
the disease course of JAS and AAS patients in the
Taiwan population. In the present study, we noted
many remarkable differences between the 2 groups,
including possible risk factors, clinical pictures, inflam-
matory markers, and radiographic evidence of hip
arthritis. However, there were no obvious disparities in
gender distribution, family history of AS, functional
limitations, most of the Bath AS indices, and radi-
ographic scoring of axial joints.
In our 169 AS patients, the male-to-female ratio
was 4.8 for the AAS group and 6.8 for the JAS group,
which is higher than the ratio of 2–3 found in other
series from Western countries.29,30 We investigated the
prevalence of possible risk factors for AS. A rather high
percentage (around 50%) of our patients, regardless of
being in the JAS or AAS group, had a family history of
AS. This might be because a patient with familial AS
would seek medical resources more readily. Also, we
found a substantial prevalence of preceding GI/GU
infection and physical trauma for both JAS and AAS
patients. More intense physical training in the JAS
group and more heavy working in the AAS group
before the onset of AS were noted. To date, it has not
been studied whether the 2 factors are connected with
the onset of AS. We suspect that both of them could
produce repeat microtrauma, which acts like physical
trauma and may facilitate the development of AS.
Moreover, we noticed that 56.4% of AAS male patients
had started to have discomfort or progressive symp-
toms during or just after being demobilized from mil-
itary service, an obligation for all Taiwanese male
citizens (not shown in table). Although most of these
people fell ill in their 3rd decade of life, the most com-
mon age of AS onset, we doubt that the intense phys-
ical training and infection from poor hygiene in the
army promoted the development of AS. Consequently,
it is worth studying the link between physical trauma
or GI/GU infection in the army and AS.
In the comparison of the clinical manifestations of
JAS and AAS patients, we noted that there was no dif-
ference between the 2 groups in the number of years
of delay in diagnosis (p = 0.358), which was contrary
to the finding of a longer delay in diagnosis of JAS
patients than AAS patients in Stone et al’s study 
(15.3 ± 0.79 years for JAS vs. 7.6 ± 0.20 years for
AAS, p < 0.001).4 The cause of earlier diagnosis in
our patients as compared with Stone et al’s might be
due to different sources of patients. Our patients were
from the rheumatology clinic of a tertiary medical
center, to which patients can have direct access 
without referral, while their patients were from the
register of the Spondylitis Association of America, a
support group for spondylitis. As for the symptoms at
disease onset, our JAS patients presented with more
peripheral enthesitis and peripheral arthritis than 
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Table 6. Treatment for juvenile-onset and adult-onset ankylosing spondylitis patients*
Management Juvenile-onset AS (n = 47) Adult-onset AS (n = 122) p†
DMARDs
Sulfasalazine 46 (97.9) 116 (95.1) 0.373
Methotrexate 6 (12.8) 5 (4.1) 0.041
Systemic steroid treatment 22 (46.8) 36 (29.5) 0.034
Antitumor necrosis factor 2 (4.3) 2 (1.6) 0.309
Symptomatic treatment (in recent 1 mo)
NSAIDs 44 (93.6) 101 (82.8) 0.053
Muscle relaxant 22 (46.8) 56 (45.9) 0.916
Acetaminophen 3 (6.4) 9 (7.4) 0.560
Anxiolytic agents 2 (4.3) 11 (9.0) 0.244
Total hip replacement 5 (10.6) 4 (3.3) 0.069
Spinal correction surgery 0 (0.0) 3 (2.5) 0.374
*Data presented as n (%); †statistical significance if p < 0.05, comparisons performed with c2 or Fisher’s exact test. DMARDs = disease-modifying
antirheumatic drugs; NSAIDs = nonsteroidal anti-inflammatory drugs.
axial symptoms, while most of the AAS patients pre-
sented with axial symptoms. During the similar dis-
ease duration, much more peripheral enthesopathy
(especially in the pelvis and heel), and arthritis of the
hip and knee were noted in JAS than in AAS patients.
Aggarwal et al found similar patterns of onset symp-
toms and peripheral joint involvement in JAS patients,
but the incidence of enthesitis was comparable in JAS
and AAS groups.31 Additionally, the prevalence of
enthesitis in our patients (97.9% in JAS, 72.1% in AAS)
was much higher than that in Aggarwal et al’s pa-
tients (40% in JAS, 37.3% in AAS). The discrepancy
might be due to us reviewing patients’ medical charts
and conducting face-to-face interviews in our study,
by which we could acquire more information about
patients’ symptoms.
There was an interesting finding of extramuscu-
loskeletal involvement in our study. The JAS group
had trends of more uveitis, IgAN, and colitis than the
AAS group, although the difference was significant
only for IgAN. Although the JAS group had slightly
but not significantly higher IgA levels, we did find
higher initial and peak IgA in patients with IgAN
compared to those without IgAN (p = 0.042, 0.043,
0.389 for initial, peak, and present IgA, respectively,
not shown in table). Previous studies noted that
around half of the patients with IgAN had elevated
serum IgA level,32 and the serum undergalactosylated
IgA1 played a critical role in this disease.33 It would
be interesting to search for the role of IgA in the
pathogenesis of JAS and IgAN in the future. On the
other hand, the contingency coefficient between uveitis
and peripheral arthritis in our AS patients was 0.155
(p = 0.041). The results correlate to those of previ-
ous studies.34,35 A matching prevalence was found be-
tween peripheral arthritis and anterior uveitis, and
HLA-linked LMP2 gene was involved in the patho-
genesis.34,35 Therefore, further studies of the relation
between peripheral arthritis and extramusculoskeletal
manifestations are expected.
An extensive comparison of several Bath AS
indices between the JAS and AAS groups was a con-
spicuous characteristic in our study. We found that
the functional impairment in JAS was nearly the same
as that in AAS. This was different from the study of
Stone et al,4 in which JAS had significantly more
functional impairment than AAS. In addition, our
study revealed notably higher CRP and ESR in the
JAS group. On the basis of more radiographic evi-
dence of hip involvement but not axial joints in JAS
patients, we deduced that peripheral joint involve-
ment correlated with elevated inflammatory markers
more than axial involvement.
In conclusion, AS tended to arise as peripheral
enthesitis or arthritis in JAS patients, while it arose from
axial joints in AAS patients. After similar disease dura-
tion, there was significantly more radiographic evidence
of hip arthritis in JAS, compared with mildly higher
(but not significant) mSASSS in AAS. We suspect that
JAS and AAS are different disease entities. The modified
New York criteria may be insufficient for early diagnosis
of JAS because the SIJ is usually intact in the first few
years of the course. In addition, the functional outcome
was not more impaired in the JAS group than the AAS
group in our study. Therefore, timely diagnosis and
treatment of JAS are very important. There are some
limitations in our study. As a retrospective study, we
acquired most data from the medical charts and recol-
lections of our patients. Furthermore, all of the subjects
being from a tertiary medical center would lead to some
biases. In future studies, we recommend larger-scale
case-control or cohort studies to search for the genetics
and pathogenesis of JAS.
References
1. Burgos-Vargas R, Pacheco-Tena C, Vazquez-Mellado J. Juvenile-
onset spondyloarthropathies. Rheum Dis Clin North Am 1997;
23:569–98.
2. Burgos-Vargas R, Vazquez-Mellado J, Cassis N, Duarte C,
Casarin J, Cifuentes M, Lino L. Genuine ankylosing spondyli-
tis in children: a case-control study of children: a case-control
study of patients with early definite disease according to adult
onset criteria. J Rheumatol 1996;23:2140–7.
3. Garcia-Morteo O, Maldonado-Cocco JA, Suarez-Almazor ME,
Garay E. Ankylosing spondylitis of juvenile onset: comparison
with adult onset disease. Scand J Rheumatol 1983;12:
246–8.
4. Stone M, Warren RW, Bruckel J, Cooper D, Cortinovis D,
Inman RD. Juvenile-onset ankylosing spondylitis is associated
with worse functional outcomes than adult-onset ankylosing
spondylitis. Arthritis Rheum 2005;53:445–51.
5. Marks SH, Barnett M, Calin A. A case-control study of juvenile-
and adult-onset ankylosing spondylitis. J Rheumatol 1982;9:
739–41.
6. O’Shea FD, Boyle E, Riarh R, Tse SM, Laxer RM, Inman RD.
Comparison of clinical and radiographic severity of juvenile-
onset versus adult-onset ankylosing spondylitis. Ann Rheum
Dis 2009;68:1407–12.
7. Reveille JD, Arnett FC. Spondyloarthritis: update on patho-
genesis and management. Am J Med 2005;118:592–603.
8. Leirisalo-Repo M, Hannu T, Mattila L. Microbial factors in
spondyloarthopathies: insights from population studies. Curr
Opin Rheumatol 2003;15:408–12.
9. Hyrich KL, Inman RD. Infectious agents in chronic rheumatic
diseases. Curr Opin Rheumatol 2001;13:300–4.
10. Cancino-Diaz M, Curiel-Quesada E, Garcia-Latorre E, Jimenez-
Zamudio L. Cloning and sequencing of the gene that codes for
the Klebsiella pneumoniae GroEL-like protein associated with
ankylosing spondylitis. Microb Pathog 1998;25:23–32.
11. Fielder M, Pirt SJ, Tarpey I, Wilson C, Cunningham P, 
Ettelaie C, Binder A. Molecular mimicry and ankylosing 
J Chin Med Assoc • November 2009 • Vol 72 • No 11 579
The differences between JAS and AAS
spondylitis: possible role of a novel sequence in pullalanase of
Klebsiella pneumoniae. FEBS Lett 1995;369:243–8.
12. Tani Y, Sato H, Tanaka N, Hukuda S. Antibodies against bac-
terial lipopolysaccharide in Japanese patients with ankylosing
spondylitis. Br J Rheum 1997;36:491–3.
13. Tiwana H, Wilson C, Walmsley RS, Wakefield AJ, Smith MS,
Cox NL, Hudson MJ. Antibody responses to gut bacteria in
ankylosing spondylitis, rheumatoid arthritis, Crohn’s disease, and
ulcerative colitis. Rheumatol Int 1997;17:11–6.
14. Jun JB, Kim TH, Jung SS, Yoo DH, Kim TY, Kim SY.
Seronegative spondyloarthropathy initiated by physical trauma.
Clin Rheumatol 2000;19:348–51.
15. Olivieri I, Gemignani G, Christou C, Semeria R, Giustarini S,
Pasero G. The triggering role of physical injury in the onset 
of peripheral arthritis in seronegative spondyloarthropathy.
Rheumatol Int 1991;10:251–3.
16. Masson G, Thomas P, Bontoux D, Alcalay M. Influence of
trauma on initiation of Reiter’s syndrome and ankylosing
spondylitis. Ann Rheum Dis 1985;44:860–2.
17. Olivieri I, Gherardi S, Bini C, Trippi D, Ciompi ML, Pasero G.
Trauma and seronegative spondyloarthropathy: rapid joint
destruction in peripheral arthritis triggered by physical activity.
Ann Rheum Dis 1988;47:73–6.
18. Wisnieski JJ. Trauma and Reiter’s syndrome: development of
“reactive arthropathy” in two patients following musculoskele-
tal injury. Ann Rheum Dis 1984;43:829–32.
19. Etiology and pathogenesis of psoriatic arthritis. In: Vasey FB,
ed. Psoriatic Arthritis. Philadelphia: Grune & Stratton, 1985:
45–57.
20. Lotz M, Carson DA, Vaughan JH. Substance P activation of
rheumatoid synoviocytes: neural pathway in pathogenesis of
arthritis. Science 1987;235:893–5.
21. Jacoby RK, Newell RLM, Hickling P. Ankylosing spondylitis
and trauma: the medicolegal implications. A comparative study
of patients with non-specific back pain. Ann Rheum Dis 1985;
44:307–11.
22. Panayi GS. Trauma and seronegative spondyloarthropathy.
Ann Rheum Dis 1989;48:879.
23. Wewers ME, Lowe NK. A critical review of visual analogue
scales in the measurement of clinical phenomena. Res in Nurs
Health 1990;13:227–36.
24. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P,
Calin A. A new approach to defining diseases status in ankylosing
spondylitis: the Bath Ankylosing Spondylitis Disease Activity
Index. J Rheumatol 1994;21:2286–91.
25. Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J,
Mallorie P, Jenkinson T. A new approach to defining functional
ability in ankylosing spondylitis: the development of the Bath
Ankylosing Spondylitis Functional Index. J Rheumatol 1994;
21:2281–5.
26. Jones SD, Steiner A, Garrett SL, Calin A. The Bath Ankylosing
Spondylitis Patient Global Score (BAS-G). Br J Rheumatol
1996;35:66–71.
27. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG,
Garrett SL, Calin A. Defining spinal mobility in ankylosing
spondylitis (AS). The Bath AS Metrology Index. J Rheumatol
1994;21:1694–8.
28. Creemers MC, Feanssen MJ, van’t Hof MA, Gribnau FW, van
de Putte LB, van Riel PL. Assessment of outcome in ankylos-
ing spondylitis: an extended radiographic scoring system. Ann
Rheum Dis 2005;64:127–9.
29. Mansour M, Cheema GS, Naguwa SM, Greenspan A, Borchers
AT, Keen CL. Ankylosing spondylitis: a contemporary perspec-
tive on diagnosis and treatment. Semin Arthritis Rheum 2007;
36:210–23.
30. Feldtkeller E, Khan MA, van der Heijde D, van der Linden S,
Braun J. Age at disease onset and diagnosis delay in HLA-B27
negative vs positive patients with ankylosing spondylitis.
Rheumatol Int 2003;23:61–6.
31. Aggarwal A, Hissaria P, Misea R. Juvenile ankylosing spondyli-
tis: is it the same as adult ankylosing spondylitis? Rheumatol Int
2005;25:94–6.
32. Clarkson AR, Seymour AE, Thompson AJ, Haynes WD, Chan
YL, Jackson B. IgA nephropathy: a syndrome of uniform mor-
phology, diverse clinical features and uncertain prognosis. Clin
Nephrol 1977;8:459–71.
33. Barratt J, Feehally J, Smith AC. The pathogenesis of IgA
nephropathy. Semin Nephrol 2004;24:197–217.
34. Maksymowych WP, Chou CT, Russell AS. Matching preva-
lence of peripheral arthritis and acute anterior uveitis in indi-
viduals with ankylosing spondylitis. Ann Rheum Dis 1995;54:
128–30.
35. Maksymowych WP, Suarez-Almazor M, Chou CT, Russell AS.
Polymorphism in the LMP2 gene influences susceptibility to
extraspinal disease in HLA-B27 positive individuals with anky-
losing spondylitis. Ann Rheum Dis 1995;54:321–4.
J Chin Med Assoc • November 2009 • Vol 72 • No 11580
Y.C. Lin, et al
